Antibodies News and Research

RSS

Targeted treatment for systemic lupus erythematosus

A team of researchers from Charité - Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus.

22 Sep 2020

Parkinson's disease diagnosed after SARS-CoV-2

As the COVID-19 pandemic continues to spread, new and unusual chronic sequelae of the disease are cropping up in many medical practices. Now, a new case paper published in The Lancet in September 2020 describes a case of new-onset Parkinson's disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2020

SARS-CoV-2 seroprevalence in Swiss schoolchildren shows most infections undiagnosed

A new study reports the seroprevalence among schoolchildren in Zurich, Switzerland. Published on the preprint server medRxiv* in September 2020, this study contributes to the current discussion on how and when to reopen schools.

22 Sep 2020

NIH expands clinical trials to evaluate convalescent plasma as a treatment for COVID-19

Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.

22 Sep 2020

Cats’ immune system can deal with SARS-CoV-2, shows study

On 8 May 2020, the Institute of Agrifood Research and Technology (IRTA) reported the case of the first cat infected with SARS-CoV-2 in Spain. It was a 4-year-old cat called Negrito, who lived with a family affected by COVID-19, with one case of death.

22 Sep 2020

Nanoparticle SARS-CoV-2 model could potentially speed the search for drugs

A team of scientists from the National Center for Advancing Translational Sciences and Naval Research Laboratory in Washington, D.C., has developed a new tool that mimics how SARS-CoV-2 -- the virus that causes COVID-19 -- infects a cell, information that could potentially speed the search for treatments against the disease.

22 Sep 2020

Study detects key differences in immune responses of adults and children with COVID-19

The first study comparing the immune responses of adults and children with COVID-19 has detected key differences that may contribute to understanding why children usually have milder disease than adults.

22 Sep 2020

A cost-effective scalable production of SARS-CoV-2 RBD in yeast

A new study by the Argentinian AntiCovid Consortium and published in the preprint server bioRxiv* in September 2020 reports on the successful characterization of the conformation and stability of the SARS-CoV-2 spike protein receptor-binding domain (RBD) in two different cell systems. This may help to accelerate the development of vaccines and neutralizing antibodies.

21 Sep 2020

Consumption of cooked carrots can also trigger allergic reactions, finds study

The consumption of raw carrots triggers allergic reactions in many people. Contrary to popular belief, cooked carrots can also have this effect.

21 Sep 2020

Oncology nurses should be routinely tested for SARS-CoV-2, warn researchers

Researchers from the NHS Foundation Trust, University of Cambridge and Cambridge Clinical Laboratories have warned that until a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) becomes available, antigen and antibody testing should be carried out among oncology nurses as part of routine patient care.

21 Sep 2020

Providing personalized care for bleeding disorders

An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders.

From Takeda 21 Sep 2020

Providing personalized care for bleeding disorders

An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders.

From Takeda 21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Large mother-child paired study promises more answers on COVID-19 in pregnancy

A new paper published in the preprint server medRxiv* in August 2020 reports the design and preliminary findings of an ongoing study on pregnant mothers and their children born during the pandemic.

20 Sep 2020

New method isolates antibody-like proteins that capture and neutralize SARS-CoV-2

Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus - 4 of which also exhibited neutralizing activity - within 4 days, according to a new study.

19 Sep 2020

New partnership aims to advance predictive tests for multiple myeloma in Ireland

By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma, the second most common blood cancer in Ireland.

18 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

T cells on the front line of COVID-19 response

In the new study, published in the journal Cell, the team has found that the uncoordinated responses produced by the immune system, especially in people who are more than 65 years old, maybe the reason why older adults are more at risk.

17 Sep 2020

Ceftazidime flagged as a potential inhibitor of the SARS-COV-2 virus

After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells.

17 Sep 2020